Lexeo Therapeutics

LXEO · Nasdaq · United States

Share price · LXEO

$2.95-1.98 (-40.16%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.8M (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when LXEO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-11.6%
  2. 16 Nov 2026+12.5%
  3. 28 Oct 2026+9.1%
  4. 13 Oct 2026-9.9%
  5. 1 Oct 2026+7.1%
  6. 29 Sep 2026+8.9%
  7. 28 Sep 2026-5.1%

    Nothing announced by LXEO that day or the session before.

  8. 23 Sep 2026-13.5%
  9. 8 Jul 2026+10.2%

    Nothing announced by LXEO that day or the session before.

  10. 20 May 2026+14.3%

Share of unusual movement by asset

For each asset, the share of LXEO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
LX1001
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—38%
Sessions with no dated event—60%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
APOE2 (gene therapy)Gene therapy / editing
Alzheimer's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (12)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$19M$96M+ $119M short-term inv.$26M-$18M operating cash flowreport ↗
View 11 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$16M$75M+ $121M short-term inv.$20M-$21M operating cash flowreport ↗
2025-Q3—$16M$44M+ $82M short-term inv.$20M-$30M operating cash flowreport ↗
2025-Q2—$15M$39M+ $97M short-term inv.$26M-$27M operating cash flowreport ↗
2025-Q1—$17M$32M+ $71M short-term inv.$33M-$22M operating cash flowreport ↗
2024-Q3—$23M$160M$29M-$18M operating cash flowreport ↗
2024-Q2—$17M$178M$21M-$20M operating cash flowreport ↗
2024-Q1—$16M$198M$22M-$15M operating cash flowreport ↗
2023-Q3—$17M$39M$20M-$14M operating cash flowreport ↗
2023-Q2—$11M$49M$13M-$13M operating cash flowreport ↗
2023-Q1—$16M$62M$19M-$18M operating cash flowreport ↗
2022-Q3$0.5M$15M$97M$17Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$64M$66M+ $119M short-term inv.$25M-$99M operating cash flowreport ↗

Lexeo Therapeutics reported no revenue for FY2025. R&D spend was $63.8M, down 13.9% YoY, and cash and equivalents were $66.25M, while cash, cash equivalents and investments totaled $246.6M at year-end. The annual net loss was $99.96M, or $1.86 per share.

Management said the $246.6M cash position is expected to fund operations into 2028. The company submitted the SUNRISE-FA 2 pivotal trial protocol and SAP for LX2006 to the FDA in Q1 2026 after a Type B meeting, with study initiation on track for 1H 2026, held an initial CMC Development and Readiness Program meeting, and presented continued positive interim data for LX2006 and LX2020 at the ACC Annual Meeting. It also established a research collaboration with Johnson & Johnson for targeted cardiac delivery of AAV gene therapy, executed a $154M equity financing in October 2025, and added a new Chief Medical Officer and senior cardiac leadership.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$74M$38M+ $87M short-term inv.$25M-$81M operating cash flowreport ↗
2023-FY—$53M$125M$17M-$60M operating cash flowreport ↗
2022-FY$0.7M$49M$81M—-$55M operating cash flowreport ↗
2021-FY——$136M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 15 sales ($739K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17Townsend Richard Nolan · director, Chief Executive OfficerOpen-market sale3,295$3.26$11KForm 4
2026-11-17Otero Jose Manuel · Chief Operating OfficerOpen-market sale1,285$3.26$4KForm 4
2026-11-17Tamayo Louis Edward · Chief Financial OfficerOpen-market sale1,007$3.26$3KForm 4
2026-11-14Schilke Tobin · directorAward / grant (derivative)70,000——Form 4
2026-09-24Tamayo Louis Edward · Chief Financial OfficerAward / grant (derivative)54,750——Form 4
2026-09-24Townsend Richard Nolan · director, Chief Executive OfficerAward / grant (derivative)145,500——Form 4
2026-09-24Otero Jose Manuel · Chief Operating OfficerAward / grant (derivative)54,750——Form 4
2026-09-24Bhalla Narinder Pal · Chief Medical OfficerAward / grant (derivative)54,750——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 138 reporting institutions held 79.9M shares ($458.2M, 101.7% of shares outstanding).

#InstitutionSharesValue
1Paradigm Biocapital Advisors LP6,184,134$35.5M
2BlackRock, Inc.5,110,871$29.3M
3Affinity Asset Advisors, LLC5,050,211$29.0M
4RA CAPITAL MANAGEMENT, L.P.5,000,000$28.7M
5JANUS HENDERSON GROUP PLC4,976,429$28.5M
6Vestal Point Capital, LP4,475,000$25.7M
7Frazier Life Sciences Management, L.P.4,424,725$25.4M
8CITADEL ADVISORS LLC3,834,999$22.0M
9ORBIMED ADVISORS LLC3,602,450$20.7M
10STATE STREET CORP3,568,242$20.5M
11VANGUARD CAPITAL MANAGEMENT LLC3,007,093$17.3M
12Woodline Partners LP2,750,532$15.8M
13GOLDMAN SACHS GROUP INC1,949,885$11.2M
14Avoro Capital Advisors LLC1,875,000$10.8M
15Point72 Asset Management, L.P.1,680,449$9.6M